Louise Chen
Stock Analyst at Scotiabank
(2.41)
# 2,434
Out of 4,893 analysts
301
Total ratings
42.51%
Success rate
-0.14%
Average return
Main Sectors:
Stocks Rated by Louise Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRPT Sarepta Therapeutics | Upgrades: Sector Outperform | $80 | $19.07 | +319.62% | 3 | Jun 6, 2025 | |
| BPMC Blueprint Medicines | Downgrades: Sector Perform | $135 | $129.33 | +4.38% | 2 | Jun 2, 2025 | |
| ACRS Aclaris Therapeutics | Maintains: Sector Outperform | $15 → $9 | $1.59 | +467.82% | 6 | May 9, 2025 | |
| EWTX Edgewise Therapeutics | Downgrades: Sector Perform | $50 → $14 | $13.84 | +1.16% | 2 | Apr 3, 2025 | |
| GANX Gain Therapeutics | Initiates: Sector Outperform | $12 | $1.77 | +577.97% | 1 | Mar 7, 2025 | |
| INVA Innoviva | Initiates: Sector Outperform | $55 | $19.06 | +188.56% | 5 | Mar 7, 2025 | |
| PTCT PTC Therapeutics | Initiates: Sector Perform | $55 | $49.51 | +11.09% | 1 | Mar 7, 2025 | |
| CATX Perspective Therapeutics | Initiates: Sector Outperform | $15 | $4.11 | +264.96% | 1 | Mar 7, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Sector Outperform | $50 | $26.43 | +89.18% | 1 | Mar 7, 2025 | |
| ARDX Ardelyx | Initiates: Sector Outperform | $15 | $4.71 | +218.81% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $17 | $10.85 | +56.68% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $70 | $31.45 | +122.58% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $50 | $8.80 | +468.18% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $30 | $17.97 | +66.94% | 1 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $55 | $34.08 | +61.38% | 8 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.85 | - | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $160 | $71.01 | +125.32% | 20 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $36.26 | - | 6 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $45 | $25.78 | +74.55% | 31 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $215 | $157.69 | +36.34% | 40 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $12.02 | - | 5 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $84.02 | +84.48% | 25 | Oct 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.57 | - | 9 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $885 | $790.65 | +11.93% | 45 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $9.72 | - | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.55 | - | 10 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $10.99 | - | 6 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $8.89 | - | 3 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $50.95 | - | 6 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $200 | $195.00 | +2.56% | 5 | Aug 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.89 | - | 3 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.51 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $17.25 | - | 2 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.31 | - | 2 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $925 | $559.76 | +65.25% | 1 | Apr 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $0.70 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $65 | $3.16 | +1,956.96% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.15 | +334.78% | 2 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $25 | $2.05 | +1,119.51% | 4 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $16.00 | +212.50% | 3 | Sep 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $50 | $15.27 | +227.44% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.19 | +320.17% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $5 → $9 | $1.38 | +552.17% | 1 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $1,687,500 | $2.63 | +64,163,398.10% | 1 | Jul 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $258 | $451.90 | -42.91% | 1 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $15 | $16.53 | -9.26% | 3 | Feb 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $2.23 | +2,142.15% | 2 | Jul 19, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.36 | +1,376.01% | 2 | Aug 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $7.22 | +523.27% | 1 | Jun 22, 2017 |
Sarepta Therapeutics
Jun 6, 2025
Upgrades: Sector Outperform
Price Target: $80
Current: $19.07
Upside: +319.62%
Blueprint Medicines
Jun 2, 2025
Downgrades: Sector Perform
Price Target: $135
Current: $129.33
Upside: +4.38%
Aclaris Therapeutics
May 9, 2025
Maintains: Sector Outperform
Price Target: $15 → $9
Current: $1.59
Upside: +467.82%
Edgewise Therapeutics
Apr 3, 2025
Downgrades: Sector Perform
Price Target: $50 → $14
Current: $13.84
Upside: +1.16%
Gain Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $1.77
Upside: +577.97%
Innoviva
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $19.06
Upside: +188.56%
PTC Therapeutics
Mar 7, 2025
Initiates: Sector Perform
Price Target: $55
Current: $49.51
Upside: +11.09%
Perspective Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $4.11
Upside: +264.96%
Palvella Therapeutics
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $26.43
Upside: +89.18%
Ardelyx
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $15
Current: $4.71
Upside: +218.81%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $17
Current: $10.85
Upside: +56.68%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $70
Current: $31.45
Upside: +122.58%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $50
Current: $8.80
Upside: +468.18%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $30
Current: $17.97
Upside: +66.94%
Mar 7, 2025
Initiates: Sector Outperform
Price Target: $55
Current: $34.08
Upside: +61.38%
Nov 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $2.85
Upside: -
Nov 6, 2024
Reiterates: Overweight
Price Target: $160
Current: $71.01
Upside: +125.32%
Nov 6, 2024
Reiterates: Overweight
Price Target: n/a
Current: $36.26
Upside: -
Oct 25, 2024
Reiterates: Overweight
Price Target: $45
Current: $25.78
Upside: +74.55%
Oct 16, 2024
Reiterates: Overweight
Price Target: $215
Current: $157.69
Upside: +36.34%
Oct 11, 2024
Reiterates: Overweight
Price Target: n/a
Current: $12.02
Upside: -
Oct 3, 2024
Reiterates: Overweight
Price Target: $155
Current: $84.02
Upside: +84.48%
Sep 19, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.57
Upside: -
Sep 16, 2024
Reiterates: Overweight
Price Target: $885
Current: $790.65
Upside: +11.93%
Sep 16, 2024
Reiterates: Overweight
Price Target: n/a
Current: $9.72
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.55
Upside: -
Aug 29, 2024
Reiterates: Overweight
Price Target: n/a
Current: $10.99
Upside: -
Aug 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.89
Upside: -
Aug 14, 2024
Reiterates: Overweight
Price Target: n/a
Current: $50.95
Upside: -
Aug 5, 2024
Reiterates: Overweight
Price Target: $200
Current: $195.00
Upside: +2.56%
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.89
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.51
Upside: -
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $17.25
Upside: -
May 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.31
Upside: -
Apr 15, 2024
Reiterates: Neutral
Price Target: $925
Current: $559.76
Upside: +65.25%
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $0.70
Upside: -
Jan 31, 2024
Reiterates: Overweight
Price Target: $65
Current: $3.16
Upside: +1,956.96%
Sep 13, 2023
Reiterates: Overweight
Price Target: $5
Current: $1.15
Upside: +334.78%
Sep 5, 2023
Reiterates: Overweight
Price Target: $25
Current: $2.05
Upside: +1,119.51%
Sep 5, 2023
Reiterates: Overweight
Price Target: $50
Current: $16.00
Upside: +212.50%
Aug 22, 2023
Reiterates: Overweight
Price Target: $50
Current: $15.27
Upside: +227.44%
Aug 17, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.19
Upside: +320.17%
May 12, 2023
Maintains: Overweight
Price Target: $5 → $9
Current: $1.38
Upside: +552.17%
Jul 7, 2021
Initiates: Overweight
Price Target: $1,687,500
Current: $2.63
Upside: +64,163,398.10%
Mar 27, 2020
Maintains: Neutral
Price Target: $240 → $258
Current: $451.90
Upside: -42.91%
Feb 12, 2020
Maintains: Neutral
Price Target: $9 → $15
Current: $16.53
Upside: -9.26%
Jul 19, 2018
Maintains: Overweight
Price Target: $40 → $50
Current: $2.23
Upside: +2,142.15%
Aug 18, 2017
Initiates: Overweight
Price Target: $20
Current: $1.36
Upside: +1,376.01%
Jun 22, 2017
Initiates: Overweight
Price Target: $45
Current: $7.22
Upside: +523.27%